METHODS FOR DETERMINING THE PRESENCE OF SARS CORONAVIRUS IN A SAMPLE
First Claim
Patent Images
1. A method for determining the presence of SARS-CoV in a test sample, said method comprising the steps of:
- a) contacting a test sample a detection probe up to 100 bases in length and comprising a target binding portion which forms a hybrid stable for detection with a target sequence contained within a SARS-CoV 5′
leader sequence or its complement, wherein said probe does not form a hybrid stable for detection with nucleic acid derived from HCoV-OC43 or HCoV-229E under said conditions; and
b) determining whether said hybrid is present in said test sample as an indication of the presence of SARS-CoV in said test sample.
4 Assignments
0 Petitions
Accused Products
Abstract
Methods for determining the presence of SARS-CoV in a test sample that include targeting the SARS-CoV 5′ leader sequence or the SARS-CoV 3′ terminal sequence.
-
Citations
17 Claims
-
1. A method for determining the presence of SARS-CoV in a test sample, said method comprising the steps of:
-
a) contacting a test sample a detection probe up to 100 bases in length and comprising a target binding portion which forms a hybrid stable for detection with a target sequence contained within a SARS-CoV 5′
leader sequence or its complement, wherein said probe does not form a hybrid stable for detection with nucleic acid derived from HCoV-OC43 or HCoV-229E under said conditions; andb) determining whether said hybrid is present in said test sample as an indication of the presence of SARS-CoV in said test sample. - View Dependent Claims (2, 3, 4, 5, 6, 7)
-
-
8. A method for amplifying a target region of nucleic acid derived from SARS-CoV, said method comprising the steps of:
-
a) contacting a test sample with one or more amplification oligonucleotides under amplification conditions, wherein a first of said amplification oligonucleotides comprises a target binding portion which binds to a target region fully contained within a SARS-CoV 5′
leader sequence or its complement under said conditions, wherein said first amplification oligonucleotide does not contain any other base sequences which stably hybridize to nucleic acid derived from SARS-CoV under said amplification conditions; andb) exposing said test sample to said conditions such that said target region, if present in said test sample, is amplified. - View Dependent Claims (9, 10, 11, 12)
-
-
13. A method for determining the presence of SARS-CoV in a test sample, said method comprising the steps of:
-
a) contacting a test sample with a detection probe up to 100 bases in length and comprising a target binding portion which forms a hybrid stable for detection with a target sequence contained within a SARS-CoV 3′
co-terminal sequence or its complement, wherein said probe forms a hybrid stable for detection with said target sequence under stringent hybridization conditions, and wherein said probe does not form a hybrid stable for detection with nucleic acid derived from HCoV-OC43 or HCoV-229E under said conditions; andb) determining whether said hybrid is present in said test sample as an indication of the presence of SARS-CoV in said test sample. - View Dependent Claims (14, 15)
-
-
16. A method for amplifying a target region of nucleic acid derived from SARS-CoV, said method comprising the steps of:
-
a) contacting a test sample with one or more amplification oligonucleotides under amplification conditions, wherein a first of said amplification oligonucleotides comprises a target binding portion which binds to a target region contained within a SARS-CoV 3′
co-terminal sequence or its complement under said conditions; andb) exposing said test sample to said conditions such that said target region, if present in said test sample, is amplified. - View Dependent Claims (17)
-
Specification